Shots:
- Telix and Regeneron have entered into a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies
- Telix will receive a $40M upfront from Regeneron for four initial programs, with options to expand. The companies will share commercialization costs and profits, while Telix may opt to earn up to $535M per program in development and commercial milestones plus low double-digit royalties, totaling up to $2.1B across programs
- The collaboration combines Telix’s radiopharmaceutical platform and manufacturing with Regeneron’s biologics and bispecific antibody expertise to target solid tumors, alongside the development of companion diagnostics from VelocImmune mice. The companies will co-develop and co-commercialize therapies under a 50/50 cost and profit-sharing model, with Telix leading diagnostic commercialization and Regeneron receiving a share of profits
Ref: Regeneron | Image: Telix and Regeneron | Press Release
Related News: Telix Reports US FDA Acceptance of NDA for TLX101-Px (Pixclara) in Glioma Imaging
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
